文献速递炎症性肠病

非洲炎症性肠病的流行病学、自然史和治疗:范围综述

Epidemiology, Natural History, and Treatment of Inflammatory Bowel Disease in Africa: A Scoping Review.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-03-15

该范围综述检索多个数据库至2024年11月,纳入268项研究、21,089例炎症性肠病患者,总结非洲炎症性肠病的发病率、患病率、环境因素、诊断、结局和管理。研究发现关于时间趋势的研究很少,生物制剂或先进治疗使用稀少,前瞻性研究少且地区代表性不均。

要点

  • 纳入268项研究,共21,089例炎症性肠病患者(克罗恩病10,426例;溃疡性结肠炎7,956例)。
  • 关于炎症性肠病时间发病率的研究很少,有限数据显示与西方相似的增加趋势。
  • 生物制剂或先进治疗的使用稀少。

核心结论

  • 关于非洲炎症性肠病危险因素、疾病负担和结局的出版物匮乏,前瞻性研究少且地区代表性存在差异,需要更多前瞻性数据以准确指导知识和管理策略。

研究设计与样本

  • 范围综述,2024年11月在MEDLINE、Embase、Web of Science、AIM、Africa Wide、Cochrane和ClinicalTrials.gov进行综合检索,按预设纳入标准筛选研究,使用Covidence提取数据。
  • 共识别6896条参考文献,最终纳入268项研究,包含21,089例炎症性肠病患者(克罗恩病10,426例;溃疡性结肠炎7,956例;未指定类型炎症性肠病329例;未分类炎症性肠病2,378例)。

主要发现

  • 关于炎症性肠病时间发病率的研究很少,在稀疏的可用数据中,可见与西方相似的增加。
  • 遗传和环境研究显示与西方队列已知关联(如环境卫生)有许多共同发现,但也突出了一些差异。
  • 生物制剂或先进治疗的使用稀少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 关于非洲炎症性肠病危险因素、疾病负担和结局的出版物匮乏。
  • 前瞻性研究少。
  • 地区代表性存在差异。
  • 需要更多前瞻性数据以准确指导知识和管理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, are global diseases. There is a paucity of knowledge about the burden and epidemiology of IBD in Africa. We performed a scoping review of the published literature on IBD in Africa to identify burden, risk factors, and outcomes as well as knowledge gaps. METHODS: A comprehensive search was conducted in MEDLINE, Embase, Web of Science, AIM, Africa Wide, Cochrane, and ClinicalTrials.gov in November 2024. Studies were screened and selected based on predefined inclusion criteria. Data extraction was conducted using Covidence. Literature was summarized focusing on the incidence and prevalence, environmental factors, diagnosis, outcomes, and management of IBD. RESULTS: Of 6896 references identified, a total of 268 studies met inclusion criteria. This included data from 21,089 patients with IBD (10,426 Crohn's disease; 7956 ulcerative colitis; 329 unspecified IBD; 2378 uncategorized IBD). There were few studies examining temporal incidence of IBD; in the sparse available data, a similar increase was notable as seen in the West. Studies of genetics and environment revealed many shared findings from known associations from Western cohorts (such as environmental hygiene) but highlight some differences as well. Use of biologic or advanced therapy was sparse. CONCLUSIONS: We identified a paucity of publications regarding the risk factors, burden, and outcomes of IBD in Africa. There were few prospective studies and regional variations in representation. There is a need for more prospective data to inform our knowledge and management strategies accurately.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Omede M, Itam-Eyo A, Park A, et al. Epidemiology, Natural History, and Treatment of Inflammatory Bowel Disease in Africa: A Scoping Review. Clin Gastroenterol Hepatol. 2025. PMID: 40090434. doi:10.1016/j.cgh.2024.12.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。